Detailed Narrative
Overall Financial Performance and Margins
Ipca Labs reported a mixed Q1 FY26. Standalone net profit increased by 26% to Rs. 262 crores, while consolidated net profit grew by 18% to Rs. 234 crores. Standalone EBITDA margin improved to 23.82% from 22.22% in Q1 FY25. However, consolidated EBITDA margin saw a marginal decline to 18.39% from 18.52% in Q1 FY25, primarily due to Unichem's performance.
Domestic Business Update
The domestic business grew by approximately 10% in Q1 FY26, maintaining its rank as 16th per IQVIA with a market share increase of 7 bps to 2.08%. While overall growth was positive, the cardiovascular therapy segment underperformed, growing only around 8% due to business reorganization and challenges in recruiting manpower for two new marketing divisions. Management expects a faster recovery in this segment.
Export Business Performance
Export branded formulation business grew by 10% to Rs. 124 crores from Rs. 113 crores in Q1 FY25. The generic business showed stronger growth at 15%, reaching Rs. 326 crores compared to Rs. 283 crores in the prior year. The API business also delivered a 12% growth. Europe and Latin America exports performed well, contributing to the overall 12% export growth.
Unichem's Challenges and Impact
Unichem's consolidated business grew by 9%, but its gross margin declined significantly. This was attributed to market share loss in four major US products, a sharp decline in Asia (Myanmar business fell from Rs. 23 crores to Rs. 8 crores due to import license issues), and a drop in Brazil business (from Rs. 21 crores to Rs. 14 crores). Additionally, Unichem incurred one-time📎 provisions of Rs. 12 crores due to Euro currency fluctuation for an EU penalty and Rs. 10 crores for the closure of its Ireland facility, further impacting profitability.
Subsidiary Performance and Outlook
Onyx Scientific, typically a strong performer, reported a loss of 300,000 sterling pound in Q1 FY26, as business from multinational companies reduced. Pisgah continues to incur losses, though in line with the previous year, with its injectable project expected to be commercially ready by H2 FY26. Management indicated that scaling up subsidiaries, including a new one in Germany, might involve initial losses, with meaningful contributions expected over a 2-3 year period.
Revised Full-Year Guidance
Ipca Labs maintained its FY26 consolidated topline growth guidance at 9%-10%. However, the consolidated EBITDA margin improvement target for FY26 was revised downwards to 75 basis points (bps) from the earlier guidance of 100 bps, primarily due to the underperformance of Unichem. Standalone EBITDA margin is still expected to improve by approximately 1.5% (150 bps) for the full year.
US Market Strategy
For the Ipca standalone US business, management expects around $15-$16 million in revenue for the current financial year from existing deal wins. Four products have already been launched, with another 4-5 products planned for launch this fiscal year. The company aims to launch 5-6 products annually in the US market going forward⏳.